Elafibranor is under clinical development by Ipsen and currently in Pre-Registration for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). According to GlobalData, Pre-Registration drugs for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Elafibranor’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Elafibranor overview
Elafibranor (GFT-505) is under development for the treatment of colitis, non-alcoholic fatty liver disease, primary biliary cholangitis (PBC), primary sclerosing cholangitis. The drug candidate is administered orally as a coated tablet. It acts by targeting peroxisome proliferator-activated receptor (PPAR) alpha and PPAR-beta / PPAR- delta. The drug candidate was under development for dyslipidemia, abdominal obesity, type 2 diabetes, Crohn’s disease, insulin resistance and glucose intolerance, colitis and NAFLD/NASH-induced hepatocellular carcinoma (HCC). It was also underdevelopment for non-alcoholic steatohepatitis, liver fibrosis.
See Also:
Ipsen overview
Ipsen is a global specialty biopharmaceutical company engaged in the manufacturing and distribution of drugs for the treatment of cancer, rare diseases, and neurological diseases, including specialty pharmaceutical products. The company develops and commercializes novel medicines for cancer, neuroscience and rare diseases and offers products to treat gastrointestinal disorders, and neurodegenerative pathologies. Ipsen sells its drugs through a network of distributors and directly to hospitals in a few countries. The company operates its research and development facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, and rest of the world. Ipsen is headquartered in Paris, France.
For a complete picture of Elafibranor’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.